



Dicerna Pharmaceuticals
Investor Relations Department
87 Cambridgepark Drive
Cambridge, MA 02140
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DRNA

Last Trade:	4.15
Trade Time:	4:00 PM ET Jul 24, 2017
Change:	0.02 (+0.484%)
Day Range	3.93 - 4.32
52-Week Range	2.42 - 6.10
Volume	379,045

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

[Dicerna Corporate Fact Sheet\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 17, 2017

[Dicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria \(PH\) and Reveals New Therapeutic Target for DCR-PHXC](#)

Jun 15, 2017

[Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Jun 8, 2017

[Dicerna Announces Appointment of Ralf Roskamp, M.D., as Chief Medical Officer](#)

Jun 1, 2017

[Dicerna to Present at Jefferies 2017 Global Healthcare Conference](#)

May 8, 2017

[Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update](#)

Financials [\[View all \]](#)

Mar 30, 2017

[Annual Report \(10-K\)](#)

May 23, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)